Atea Pharmaceuticals, Inc. Stockholders Equity

Quick Answer

Atea Pharmaceuticals, Inc. reported Stockholders Equity of $275.43 million for fiscal year 2025.

Atea Pharmaceuticals, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $275.43M -37.2%
2024 $438.87M -21.0%
2023 $555.19M -13.3%
2022 $640.57M -9.8%
2021 $710.08M +29.6%
2020 $547.80M +1205.1%
2019 -$49.57M -37.1%
2018 -$36.16M -31.4%
2017 -$27.51M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $315.78M -31.1% -13.3%
June 30, 2025 $364.42M -23.5% -11.4%
March 31, 2025 $411.08M -18.5% -6.3%
December 31, 2024 $438.87M -21.0% -4.3%
September 30, 2024 $458.52M -21.2% -3.8%
June 30, 2024 $476.47M -20.9% -5.5%
March 31, 2024 $504.37M -18.4% -9.2%
December 31, 2023 $555.19M -13.3% -4.6%
  • Atea Pharmaceuticals, Inc. showed a decrease of -37.2% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2017–2025 period, Atea Pharmaceuticals, Inc.’s stockholders equity has grown by 1101.2% (from -$27.51 million to $275.43 million).
  • The most recent figure is from Atea Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment